Organization
Yantai LNC Biotechnology Singapore
5 clinical trials
Clinical trial
Phase I, Open-Label Study of the Safety and Dosimetry of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in Adult Patients With Advanced Fibroblast Activation Protein (FAP)-Positive Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-10
Clinical trial
Phase I, Open-Label Study of the Safety and Dosimetry of a 3-Dose Regimen of Escalating Doses of 177Lu-LNC1003 Injection in Adult Patients With Prostate Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Status: Not yet recruiting, Estimated PCD: 2025-11-07
Clinical trial
A Multicenter, Open, Non-inferiority Phase III Clinical Study to Evaluate the Efficacy of 18F-Alfatide Injection PET/CT Compared With 18F-FDG PET/CT in the Diagnosis of Lymph Node Metastasis in Non-small Cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Clinical trial
Phase I Clinical Trial of the Safety, Pharmacokinetics, Biodistribution and Dosimetry of 68Ga-LNC1007 Injection in Adult Healthy Volunteers and Solid Tumor PatientsStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase I Clinical Trial of 18F-LNC1007 Injection PET/CT in Healthy Volunteers and Light Tumor Burden Patients for Evaluating Its Pharmacokinetics, Biodistribution,Dosimetry and SafetyStatus: Not yet recruiting, Estimated PCD: 2024-09-01